Effects of selective cyclooxygenase isoform inhibition on systemic prostacyclin synthesis and on platelet function at rest and after exercise in healthy volunteers

Platelets

Volumn 18, Issue 5, 2007, Pages 379-385

  Weber, Artur Aron ^a,c   Heim, Hans Karl ^b   Schumacher, Marc ^a   Schrör, Karsten ^a   Hohlfeld, Thomas ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Federal Institute for Drugs and Medical Devices Bundesinstitut für Arzneimittel und Medizinprodukte   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Cycloxygenase; Exercise; Platelets; Prostacyclin; Thromboxane A2

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; BIOLOGICAL MARKER; CYCLIC AMP; CYCLIC GMP; CYCLOOXYGENASE 1; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ISOENZYME; PROSTACYCLIN; PROSTAGLANDIN SYNTHASE; ROFECOXIB; THROMBOXANE; THROMBOXANE B2;

ADULT; ARTICLE; ATHEROSCLEROSIS; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG URINE LEVEL; ENZYME INHIBITION; ENZYME SYNTHESIS; EXERCISE; FATTY ACID BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; HYPOTHESIS; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REST; RISK ASSESSMENT; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOSIS;

ADENOSINE DIPHOSPHATE; ADULT; ASPIRIN; ATHEROSCLEROSIS; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DOUBLE-BLIND METHOD; ENDOTHELIUM; EPOPROSTENOL; EXERCISE; HUMANS; ISOENZYMES; LACTONES; MALE; PLATELET ACTIVATION; REST; RISK FACTORS; SULFONES; THROMBOSIS; THROMBOXANE B2;

EID: 34547233817     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.1080/09537100601115919     Document Type: Article

References (43)

1. Gawatz M. Blood platelets. Stuttgart: Thieme, 2001.
2. Bartsch P. Platelet activation with exercise and risk of cardiac events. Lancet 1999;354:1474-1478.
3. Wang JS, Jen CJ, Chen H-I. Effects of exercise training and deconditioning on platelet function in men. Arterioscler Thromb Vasc Biol 1995;15:1668-1674.
4. Wang JS, Cheng L-J. Effect of strenuous, acute exercise on α2-adrenergic agonist-potentiaged platelet activation. Arterioscler Thromb Vasc Biol 1999;19:1559-1565.
5. Li N, Wallén NH, Hjemdahl P. Evidence for prothrombotic effects of exercise and limited protection by aspirin. Circulation 1999;100:1374-1379.
6. Broadley AJM, Gapper P, Schmitt M, Frenneaux MP. Supine rest reduces platelet activation and aggregation. Platelets 2003;14:3-7.
7. El Sayed MS, Ali N, El-Sayed Ali Z. Effects of exercise on blood coagulation, fibrinolysis and platelet aggregation. Sports Med 1996;22:282-289.
8. Willich SN, Lewis M, Löwel H, Arntz H-R, Schubert F, Schröder R. Physical exertion as a trigger of acute myocardial infarction. N Engl J Med 1993;329:1684-1690.
9. Dimsdale J, Moss J. Plasma catecholamines in stress and exercise. JAMA 1980;243:240-242.
10. Mazzeo RS. Catecholamine responses to acute and chronic exercise. Med Sci Sports Exerc 1991;23:433-453.
11. El-Sayed MS. Exercise and training effects on platelets in health and disease. Platelets 2002;13:261-266.
12. Broadley AJM, Schmitt M, Frenneaux MP. Inhibition of platelet aggregation by nitric oxide donors improves with rest. Platelets 2003;14:347-349.
13. Hilberg T, Eichler E, Gläser D, Prasa D, Stürzebecher J, Gabriel HHW. Blood coagulation and fibrinolysis before and after exhaustive exercise in patients with IDDM. Thromb Haemost 2003;90:1065-1073.
14. Wang JS, Jen CJ, Chen H-I. Effects of short-term exercise on female platelet function during different phases of the menstrual cycle. Arterioscler Thromb Vasc Biol 1997;17:1682-1686.
15. Smith WL, Garavito RM, DeWitt RM. Prostaglandin endoperoxide H synthases (cyclooxygenases)-1 and -2. J Biol Chem 1996;271:33157-33160.
16. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Ann Rev Pharmacol Toxicol 1998;38:97-120.
17. FitzGerald GA. COX-2 and beyond: Approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discov 2003;2:879-890.
18. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, GitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci USA 1999;96:272-277.
19. Catella-Lawson F, McAdam B, Morrison BW, Kapoor S, Kujubu D, Antes L, Lasseter KC, Quan H, Gertz BJ, FitzGerald GA. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999;289:735-741.
20. Grosser T, Fries S, FitzGerald G. Biological basis for the cardiovascular consequences of COX-2 inhibition: Therapeutic challenges and opportunities. J Clin Invest 2006;116:4-15.
21. Hermann A, Rauch BH, Braun M, Schrör K, Weber A-A. Platelet CD40 ligand (CD40L) - subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001;12:74-82.
22. Weber A-A, Schrör K. Differential inhibition of adenosine diphosphate versus thrombin receptor-activating peptidestimulated platelet fibrinogen binding by abciximab due to different glycoprotein IIb/IIIa activation kinetics. Blood 2001;98:1619-1621.
23. Weber A-A, Liesener S, Schanz A, Hohlfeld T, Schrör K. Habitual smoking causes an abnormality in platelet thromboxane A2 metabolism and results in an altered susceptibility to aspirin effects. Platelets 2000;11:177-182.
24. Weber A-A, Przytulski B, Schanz A, Hohlfeld T, Schrör K. Towards a definition of aspirin resistance: A typological approach. Platelets 2002;13:37-40.
25. Weber A-A, Hohlfeld T, Schrör K. cAMP is an important messenger for ADP-induced platelet aggregation. Platelets 1999;10:238-241.
26. Weber A-A, Reimann S, Schrör K. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro. Br J Pharmacol 1999;126:415-420.
27. Lindemann S, Klingel B, Fisch A, Meyer J, Darius H. Increased platelet sensitivity towards platelet inhibitors during physical exercise in patients with coronary artery disease. Thromb Res 1999;93:51-59.
28. Hilberg T, Schmidt V, Gläser D, Schammne D, Lösche W, Gabriel HHW. Platelet activity, sensitivity to agonist, and platelet-leukocyte conjugate formation after long-term exercise. Platelets 2002;13:273-277.
29. Hilberg T, Gläser D, Schmidt V, Lösche W, Franke G, Schneider K, Gabriel HHW. Short-term exercise and platelet activity, sensitivity to agonists, and platelet-leukocyte conjugate formation. Platelets 2003;14:67-74.
30. Hilberg T, Eichler E, Gläser D, Schmidt V, Gabriel HHW. Platelet activity, reactivity and platelet-leukocyte conjugate formation before and after exhaustive or moderate exercise in patients with IDDM. Platelets 2004;15:101-109.
31. 2 in healthy men: Effect of β-adrenergic blockade. J Cardiovasc Pharmacol 1984;6:449-454.
32. Lemne C, Vesterqvist O, Egberg N, Green K, Jogestrand T, de Faire U. Platelet activation and prostacyclin release in essential hypertension. Prostaglandins 1992;44:219-235.
33. Todd MK, Goldfarb AH, Burleson C. Comparison of methods for evaluating exercise-induced changes in thromboxane B2 and -thromboglobulin. Med Sci Sports Exercise 1997;29:700-704.
34. Belton O, Byrne D, Kearney D, Leahey A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation 2000;102:840-845.
35. FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984;310:1065-1068.
36. Fitzgerald DJ, Roy L, Catella F, FitzGerald GA. Platelet activation in unstable coronary disease. N Engl J Med 1986;315:983-989.
37. Glenn JR, Heptinstall S. Evidence that adenosine diphosphate can activate adenylate cyclase via conversion to adenosine in platelet-rich plasma containing magnesium. Thromb Haemost 1998;80:321-325.
38. Hardy E, Glenn J, Heptinstall S, Rubin PC, Horn EH. Magnesium modifies the responses of platelets to inhibitory agents which act via cAMP. Thromb Haemost 1995;74:1132-1137.
39. Pistono M, Bergerone S, Carrieri L, Paglia I, Stefano D, Capizzi A, Ferri M, Pescarmona G, Bosia A, Trevi G. Platelet cyclic GMP levels in unstable angina and myocardial infarction. Platelets 2003;13:307-311.
40. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000;343:1520-1528.
41. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, Makuch R, Eisen G, Agrawal NM, Stenson WF et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000;284:1247-1255.
42. Wallberg-Jonsson S, Cederfelt M, Rantapaa Dahlquist S. Hemostatic factors and cardiovascular disease in active rheumatoid arthritis: An 8 year follow up study. J Rheumatol 2000;27:717-5.
43. DeMaria AN. Relative risk of cardiovascular events in patients with rheumatoid arthritis. Am J Cardiol 2002;89:33D-38.